# Bioinformatic RNA-Seq Functional Profiling of the Tumor Suppressor Gene OPCML in Ovarian Cancers: The Multifunctional, Pleiotropic Impacts of Having Three Ig Domains

**Authors:** Adam G. Marsh, Franziska Görtler, Sassan Hafizi, Hani Gabra

PMC · DOI: 10.3390/cimb47060405 · Current Issues in Molecular Biology · 2025-05-29

## TL;DR

This study explores how the tumor suppressor gene OPCML affects ovarian cancer by analyzing RNA-Seq data and identifying key signaling pathways and genes linked to its function.

## Contribution

The study identifies new RTK transcriptomic linkages to KIT, TEK, and ROS1 in ovarian cancer and validates their connection to OPCML.

## Key findings

- OPCML regulates RTK signaling pathways PI3K/AKT and MEK/ERK in ovarian cancer.
- Three new RTK transcriptomic linkages to KIT, TEK, and ROS1 are identified.
- Extracellular signaling receptor ligands are transcriptionally linked to OPCML.

## Abstract

The IgLON family of tumor suppressor genes (TSG) impact a variety of cellular processes involved in cancer and non-cancer biology. OPCML is a member of this family and its inactivation is an important control point in oncogenesis and tumor growth. Here, we analyze RNA-Seq expression ratios in ovarian cancers from The Cancer Genome Atlas (TCGA) (189 subjects at Stage III) to identify genes that exhibit a cooperative survival impact (via Kaplan–Meier survival curves) with OPCML expression. Using enrichment analyses, we reconstruct functional pathway impacts revealing interactions of OPCML, and then validate these in independent cohorts of ovarian cancer. These results emphasize the role of OPCML’s regulation of receptor tyrosine kinase (RTK) signaling pathways (PI3K/AKT and MEK/ERK) while identifying three new potential RTK transcriptomic linkages to KIT, TEK, and ROS1 in ovarian cancer. We show that other known extracellular signaling receptor ligands are also transcriptionally linked to OPCML. Several key genes were validated in GEO datasets, including KIT and TEK. Considering the range of OPCML impacts evident in our analyses on both external membrane interactions and cytosolic signal transduction, we expand the understanding of OPCML’s broad cellular influences, demonstrating a multi-functional, pleiotropic, tumor suppressor, in keeping with prior published studies of OPCML function.

## Linked entities

- **Genes:** OPCML (opioid binding protein/cell adhesion molecule like) [NCBI Gene 4978], KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815], TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010], ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098]
- **Diseases:** ovarian cancer (MONDO:0005140)

## Full-text entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010] {aka CD202B, GLC3E, TIE-2, TIE2, VMCM, VMCM1}, KIT (KIT proto-oncogene, receptor tyrosine kinase) [NCBI Gene 3815] {aka C-Kit, CD117, MASTC, PBT, SCFR}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, OPCML (opioid binding protein/cell adhesion molecule like) [NCBI Gene 4978] {aka IGLON1, OBCAM, OPCM}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}
- **Diseases:** Cancer (MESH:D009369), TSG (OMIM:601308), Ovarian Cancers (MESH:D010051), oncogenesis (MESH:D063646)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12191799/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12191799/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12191799/full.md

---
Source: https://tomesphere.com/paper/PMC12191799